HealthTree Logo
search more_vert
close
person Sign In / Create Account
Dr. Frits van Rhee of UAMS discusses Total Therapy, his approach to address high-risk patient needs, and the importance genetic and imaging tests and how these pinpoint prognosis and best treatment path options
Dr. Frits van Rhee of UAMS discusses Total Therapy, his approach to address high-risk patient needs, and the importance genetic and imaging tests and how these pinpoint prognosis and best treatment path options image
HealthTree Podcast for Multiple Myeloma
event Oct 08, 2013 / 11:00AM MDT

Event Description

Dr. Frits van Rhee, MD, PhD, University of Arkansas for Medical Sciences

Interview date: October 4, 2013

Dr. Frits van Rhee of the University of Arkansas for Medical Sciences shares how Total Therapy is modeled after the approach in childhood acute lymphoblastic leukemia that showed dramatic results (from 5% to 90% remission rates). He describes the importance, and pros and cons of each of the diagnostic tests including cytogenetics, FISH, gene expression profiling and imaging studies. He shares how new disease growth can show up on imaging studies even before they are presented in blood or bone marrow samples. He explains that with the use of the genetic profile test, all UAMS patients are separated into two subgroups - high risk and standard risk. He explains how he tailors treatment for each sub-type and how they are using different approaches for high-risk patients including shortened treatment-free intervals with more frequent, but lower doses of chemotherapy and other combination therapies. He also describes how high-risk patients are being treated in an open study with an immunotherapy, expanded natural killer (NK) cells. He shares his opinion that the highest unmet needs currently in myeloma are treatments for high-risk patients and describes a way to find the low-hanging fruit: finding and using existing therapies effective and available for other cancers with similar genetic profiles. He describes the advantage that UAMS has in the ability to follow their patients over the long-term and how that enables them to see large numbers of patient populations divided into subgroups and better tailor personalized treatment.

Schedule & Agenda

person
Discussion
11:00AM
Dr Frits van Rhee & Jenny Ahlstrom

Speakers & Moderators

The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Sanofi
GSK
Regeneron
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube